Use your browser's back button to choose another title or click here for a New Search.

How to Get the Poster

 Download PDF (free)


Bookmark and Share





Baseline Characteristics of the Opioid Use Disorder Population Enrolled in NIDA-CTN-0051, "Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT)."

Poster presented at the College on Problems of Drug Dependence (CPDD) annual meeting, Montreal, Canada, June 17-22, 2017.

Patricia Novo, MPA, MPH (NYU School of Medicine, GNY Node), Edward V. Nunes, MD (Columbia University, GNY Node), Jennifer Scodes, MD (Columbia University, GNY Node), Martina Pavlicova, PhD (Columbia University, GNY Node), Joshua D. Lee, MD (NYU School of Medicine), Jeanine May, PhD (Emmes Corporation), Dagmar Salazar, MS (Emmes Corporation), Dikla Shmueli-Blumberg, PhD (Emmes Corporation), John Rotrosen, MD (NYU School of Medicine).

This poster describes the population enrolled in the "Extended-Release Naltrexone vs. Buprenorphine for Opioid Treatment (X:BOT)" CTN study (CTN-0051), a comparative effectiveness trial assessing extended release injectable naltrexone (XR-NTX) versus buprenorphine-naloxone (BUP-NX) as pharmacotherapeutic aids to recovery amongst treatment-seeking participants with opioiud use disorder. Baseline data about participants collected includes demographics, opioid use, and clinical characteristics, such as depression, hepatitis B and C status, and pain. Secondary aims are to examine subsets of the population, such as those with high levels of opioid use prior to the start of treatment. (Poster, PDF, English, 2018)

Keywords: Buprenorphine/Naloxone | Naltrexone | Opioid dependence | Pharmacological therapy | College on Problems of Drug Dependence (CPDD) annual meeting, 2017

Document No: 1320.

Submitted by Patricia Novo, GNY Node, 7/24/2018.

Lee, Joshua D.
May, Jeanine
Novo, Patricia
Nunes, Edward V.
Pavlicova, Martina
Rotrosen, John
Salazar, Dagmar
Shmueli-Blumberg, Dikla
Scodes, Jennifer
NIDA-CTN-0051 www

dark blue line
Supported by a grant from the National Institute on Drug Abuse to the University of Washington Alcohol and Drug Abuse Institute.
The materials on this site have neither been created nor reviewed by NIDA.
Updated 7/2018 --
dark blue line